Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.52 |
| ▸ | CDK7 | P50613 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701562 | 0.90 | KDR (0.64) | KDRCHEK1CDK7 | |
| SCHEMBL4301105 | 0.82 | CHEK1 (0.76) | KDRCHEK1CDK7 | |
| SCHEMBL4287509 | 0.81 | CHEK1 (0.71) | KDRCHEK1CDK7 | |
| SCHEMBL13701560 | 0.78 | KDR (0.81) | KDR | |
| SCHEMBL6183208 | 0.76 | NPC1 (0.66) | KDRALDH1A1LMNALCK | |
| SCHEMBL6179920 | 0.76 | KDR (1.00) | KDRCDK7LCK | |
| SCHEMBL4301212 | 0.74 | CHEK1 (0.72) | CHEK1CDK7 | |
| SCHEMBL6179560 | 0.74 | KDR (0.78) | KDRLCK | |
| SCHEMBL6180047 | 0.73 | KDR (0.77) | KDRCDK7LCK | |
| SCHEMBL4298848 | 0.73 | CHEK1 (0.72) | KDRCHEK1CDK7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233896-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | KDR 3027/4885CHEK1 1/4885CDK7 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.